Shares of Omeros Corporation (NASDAQ:OMER) have received a consensus recommendation of “Buy” from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $32.61.

OMER has been the subject of a number of recent research reports. Zacks Investment Research downgraded Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. BidaskClub downgraded Omeros Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, June 28th. Cowen and Company restated an “outperform” rating on shares of Omeros Corporation in a research note on Saturday, June 3rd. Cantor Fitzgerald restated a “hold” rating and set a $19.00 price target (up from $15.00) on shares of Omeros Corporation in a research note on Thursday, August 24th. Finally, Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Omeros Corporation in a research note on Wednesday, June 14th.

Several hedge funds have recently bought and sold shares of the company. National Asset Management Inc. purchased a new position in Omeros Corporation in the 1st quarter worth approximately $158,000. Legal & General Group Plc lifted its holdings in Omeros Corporation by 7.8% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Omeros Corporation in the 1st quarter worth approximately $292,000. Highbridge Capital Management LLC purchased a new position in Omeros Corporation in the 1st quarter worth approximately $330,000. Finally, American International Group Inc. lifted its holdings in Omeros Corporation by 15.2% in the 1st quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock worth $371,000 after purchasing an additional 3,232 shares in the last quarter. 44.93% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Corporation (NASDAQ:OMER) traded down 0.52% during midday trading on Friday, reaching $20.88. 273,157 shares of the company’s stock traded hands. Omeros Corporation has a one year low of $7.20 and a one year high of $27.09. The stock’s 50 day moving average price is $21.36 and its 200-day moving average price is $18.18. The stock’s market cap is $935.49 million.

Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.12. The business had revenue of $17.15 million during the quarter, compared to the consensus estimate of $14.63 million. Omeros Corporation’s quarterly revenue was up 71.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.32) earnings per share. Equities analysts predict that Omeros Corporation will post ($1.30) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Omeros Corporation (OMER) Receives Consensus Recommendation of “Buy” from Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/23/omeros-corporation-omer-receives-consensus-recommendation-of-buy-from-brokerages.html.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.